TECHWIRE 30
(CIX: WRAL30)  1,123.00  up arrow+1.19  (0.11 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NQ: Apple)  100.96  down arrow-0.83  (-0.82 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NY: QUINTILES)  57.32  up arrow+0.32  (0.56 %)  Updated: 06:40 PM EDT, Sep 19 2014
(OP: BASF SE)  99.23  down arrow-0.02  (-0.02 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NQ: BioCryst)  10.93  down arrow-0.17  (-1.53 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NQ: BioDelivery)  17.02  down arrow-0.33  (-1.9 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NQ: CEMP)  9.92  down arrow-0.23  (-2.27 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NQ: Cisco Systems)  25.20  down arrow-0.02  (-0.08 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NQ: Cree)  42.16  down arrow-1.06  (-2.45 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NQ: DARA)  1.18  up arrow+0.07  (6.31 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NY: EMC CORPORATION)  29.53  down arrow-0.19  (-0.64 %)  Updated: 06:40 PM EDT, Sep 19 2014
(NQ: Extreme Networks)  4.80  down arrow-0.13  (-2.64 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NQ: FB)  77.91  up arrow+0.91  (1.18 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NY: GLAXOSMITHKLINE)  47.38  up arrow+0.09  (0.19 %)  Updated: 06:40 PM EDT, Sep 19 2014
(NQ: GOOG)  596.08  up arrow+6.81  (1.16 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NY: IBM)  194.00  up arrow+0.25  (0.13 %)  Updated: 06:40 PM EDT, Sep 19 2014
(NY: LH)  106.12  up arrow+0.06  (0.06 %)  Updated: 06:40 PM EDT, Sep 19 2014
(OP: Lenovo Group)  31.10  down arrow-0.07  (-0.22 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NY: MRK)  60.49  up arrow+0.18  (0.3 %)  Updated: 06:40 PM EDT, Sep 19 2014
(NQ: Microsoft Corp)  47.52  up arrow+0.84  (1.8 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NQ: NTAP)  43.00  down arrow-0.4  (-0.92 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NY: NOVARTIS AG)  93.90  down arrow-0.9  (-0.95 %)  Updated: 06:40 PM EDT, Sep 19 2014
(OP: Novozymes A/S)  44.80  up arrow+0.06  (0.13 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NY: PFIZER)  30.40  down arrow-0.18  (-0.59 %)  Updated: 06:40 PM EDT, Sep 19 2014
(NQ: Pozen)  7.89  down arrow-0.05  (-0.63 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NY: RED HAT)  57.93  down arrow-2.73  (-4.5 %)  Updated: 06:40 PM EDT, Sep 19 2014
(NQ: BBRY)  10.89  up arrow+0.14  (1.3 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NQ: Salix)  164.23  up arrow+4.46  (2.79 %)  Updated: 08:10 PM EDT, Sep 19 2014
(NQ: SQI)  15.96  down arrow-0.39  (-2.39 %)  Updated: 08:10 PM EDT, Sep 19 2014

Posts tagged “LabCorp”

April 1

Premium Lock BD reboots startup program; NePhroGenex clinical trial; Red Hat Summit; OxyBio update; LabCorp board shuffle

Bulldog In the latest Bulldog roundup of life science and technology news: BD Technologies re-launches incubator program; NePhroGenex reports a loss for 2013 but secures providers for big clinical trial; Red Hat adds IBM exec to Summit lineup; OxyBio can resume testing; and LabCorp shuffles board.

March 25

Premium Lock Google Glass goes for style; Box plans IPO; nCino, LabCorp name new execs; Disney makes YouTube play

Bulldog The latest Bulldog roundup: Google Glass goes for fashion in deal with Ray-Ban, Oakley; web storage startup Box is going public; cloud banking firm nCino adds a VP for revenue and strategy; LabCorp hires a new CFO; and Disney is buying Maker Studios for $500 million.

February 7

Premium Lock Payment challenges chip at LabCorp revenue as earnings miss

LabCorp LabCorp (NYSE:LH) processed more tests in the fourth quarter than it did same period in the prior year but it made less money per test and the laboratory testing and diagnostics firm's revenue and earnings results fell short of analyst estimates.

Updated January 13

Premium Lock LabCorp launches new genetics-based breast cancer test

Cancer research LabCorp is among the first laboratories offering NanoString Technologies' prognostic breast cancer test, which has been shown in studies to offer better information compared to existing cancer assays.

December 5, 2013

Premium Lock LabCorp breast cancer test faces patent infringement claim from Myriad Genetics

DNA   Myriad Genetics, the company that went all the way to the U.S. Supreme Court seeking patents on human genes, now claims LabCorp's new genetic tests for breast cancer infringe on its patents. Read more about the suit.

October 29, 2013

Premium Lock Former Intersouth exec Garheng Kong joins board at LabCorp

Garheng Kong, a former partner at venture capital firm Intersouth Partners in Durham, is the newest member of the board at lab testing giant LabCorp.

Garheng Kong Garheng Kong

October 18, 2013

Premium Lock LabCorp CFO Hayes to retire in 2014

LabCorp After 17 years at LabCorp, CFO Brad Hayes plans to retire from the laboratory testing and diagnostics company next year.

August 8, 2013

Premium Lock LabCorp laying off 200 in California

LabCorp The layoffs affect workers at LabCorp locations in Irvine, Calif. and Los Angeles.

July 19, 2013

Premium Lock Higher costs cut into LabCorp's 2Q profit

LabCorp Despite posting revenue gains, LabCorp's profit was hurt by rising costs.

April 19, 2013

Premium Lock LabCorp's earnings, revenue fall shy of analyst estimates

LabCorp LabCorp said that margins were negatively affected by weather, Medicare payment reductions and the number of days in the quarter.

Updated April 2, 2013

Premium Lock LabCorp lands five-year biomarker test deal with Squibb

LabCorp The lab testing giant signs a contract for services and biomarker testing with Bristol-Myers Squibb. LabCorp also says it is expanding tests related to inflammatory bowel disease.

February 8, 2013

Premium Lock LabCorp launching $1B share buyback program

LabCorp LabCorp, the lab testing giant, said Friday it is launching a $1 billion share buyback program.

October 12, 2012

Premium Lock Former LabCorp CEO, chairman to retire from board

LabCorp Thomas Mac Mahon, chief executive officer at LabCorp for a decade who then became the firm;s chairman, is retiring from the board of directors.

August 21, 2012

Premium Lock LabCorp plans to sell $1 billion in bonds

LabCorp The lab testing firm, which earlier this month was the subject of leveraged buyout rumors on Wall Street, is selling bonds in two $500 million packages.

Updated August 2, 2012

Premium Lock LabCorp denies any knowledge of a possible buyout

LabCorp The lab testing firm, which is based in Burlington, says it is "aware" of possible buyout talk but says it's "not in current discussions."

June 5, 2012

Premium Lock LabCorp nears $2B in deals as acquisition binge continues

The Burlington-based company's latest deal - $241 million for Medtox Scientific - is just the latest in a series of acquisitions made over the past three years.

Timeline tracks LabCorp's history, growth Timeline tracks LabCorp's history, growth

June 4, 2012

Premium Lock LabCorp to acquire testing services firm in $241M deal

LabCorp Burlington-based Laboratory Corporation of America agrees to buy Medtox Scientific in an all-cash deal worth $241 million.

May 24, 2012

Premium Lock LabCorp to develop new lupus inflammation

LabCorp Burlington-based LabCorp will work with XDx to develop a biomarker and commercialize a test for the flares -- extended periods of activity for the autoimmune disease. Lupus causes the body's immune system to attack its own tissues, which leads to inflammation and organ damage.

April 5, 2012

Premium Lock LabCorp licenses new Alzheimer's disease diagnostic

Alzheimer's Alzheimer's disease affects more than five million people in the United States and more than 35 million worldwide. There are no specific tests available to detect Alzheimer's disease and track its progression. Diagnosis is currently conducted by behavioral and cognitive measurements.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Scroll